摘要
尽管不同类型癌症患者的存活率有所提高,但抗肿瘤药物引起的心脏毒性仍然是一个关键问题。炭疽热治疗后心功能不全Ines在历史上一直是一个主要问题。然而,靶向治疗和生物分子也可以诱发可逆和不可逆转的心功能不全。在过去的几年里,癌症免疫类人猿已进化为临床治疗范围广泛的固体和造血恶性肿瘤,先前被赋予了不良的预后。免疫检查点抑制剂是最前沿的免疫治疗:细胞毒性T淋巴细胞相关抗原4(CTLA-4)和程序性细胞死亡1(Pd-1)及其配体Pd-L1的靶向作用。ipilimumab(抗CTLA-4)iS是检查点抑制剂的教父,而针对pd-1(nivolumab和pbrobrolizumab)和pd-l1(atezolizumab、durvalumab、avelumab和bms-946559)的几种阻断单克隆抗体则是他们的教父。e已开发。CTLA-4和Pd-1/Pd-L1通路抑制剂可释放抗肿瘤免疫,介导肿瘤消退。虽然ctla-4抑制剂和pd-1和pd-l1阻断剂是常见的。Ly与广泛的免疫相关不良事件有关,心脏毒性一直被低估.然而,早期的动物研究已经证明,在ctla-4抑制和pd-1 del之后。可发生自身免疫性心肌炎。此外,PD-1和PD-L1可在鼠和人心肌细胞中表达.在过去的几年里,有几例致命心力衰竭的病例被记录在案。黑色素瘤患者用检查点抑制剂治疗。最近与检查点抑制剂有关的心血管毒性效应的经验介绍了重要的生物和clin概念。与未来的肿瘤学试验和临床实践密切相关。
关键词: 癌症,心脏毒性,检查点,CTLA-4,黑色素瘤,心肌炎,PD-1,PD-L1。
Current Medicinal Chemistry
Title:Immune Checkpoint Inhibitors and Cardiac Toxicity: An Emerging Issue
Volume: 25 Issue: 11
关键词: 癌症,心脏毒性,检查点,CTLA-4,黑色素瘤,心肌炎,PD-1,PD-L1。
摘要: Although survival of patients with different types of cancer has improved, cardiotoxicity induced by anti-neoplastic drugs remains a critical issue. Cardiac dysfunction after treatment with anthracyclines has historically been a major problem. However, also targeted therapies and biological molecules can induce reversible and irreversible cardiac dysfunction. Over the last years, cancer immunotherapies haverevolutionized the clinical management of a wide spectrum of solid and hematopoietic malignancies previously endowed with poor prognosis. Immune checkpoint inhibitors are at the forefront of immunotherapy: the two most prominent are the targeting of cytotoxic-T-lymphocyte-associated antigen 4 (CTLA- 4) and of programmed cell death 1 (PD-1) and its ligand PD-L1. Ipilimumab (anti-CTLA-4) is the godfather of checkpoint inhibitors, whereas several blocking monoclonal antibodies targeting PD-1 (nivolumab and pembrolizumab) and PD-L1 (atezolizumab, durvalumab, avelumab, and BMS-946559) have been developed. Inhibitors of CTLA-4 and PD-1/PD-L1 pathway can unleash anti-tumor immunity and mediate cancer regressions. Although CTLA-4 inhibitors and PD-1 and PD-L1 blocking agents are frequently associated with a wide spectrum of immune-related adverse events, cardiac toxicity has been underestimated. However, early animal studies have demonstrated that after CTLA-4 inhibition and PD-1 deletion autoimmune myocarditis can occur. Moreover, PD-1 and PD-L1 can be expressed in rodent and human cardiomyocytes. During the last years several cases of fatal heart failure have been documented in melanoma patients treated with checkpoint inhibitors. The recent experience with cardiovascular toxic effects associated with checkpoint inhibitors introduces important concepts biologically and clinically relevant for future oncology trials and clinical practice.
Export Options
About this article
Cite this article as:
Immune Checkpoint Inhibitors and Cardiac Toxicity: An Emerging Issue, Current Medicinal Chemistry 2018; 25 (11) . https://dx.doi.org/10.2174/0929867324666170407125017
DOI https://dx.doi.org/10.2174/0929867324666170407125017 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Prognostic Relevance of Metabolic Approach in Patients with Heart Failure
Current Pharmaceutical Design MicroRNAs: Potential Diagnostic and Therapeutic Targets for Breast Cancer
Epigenetic Diagnosis & Therapy (Discontinued) Incidence and Prevalence of Hypothyroidism in Patients Affected by Chronic Heart Failure: Role of Amiodarone
Endocrine, Metabolic & Immune Disorders - Drug Targets Hypertension - Current Natural Strategies to Lower Blood Pressure
Current Pharmaceutical Design Disentangling the Intricacies of Migraine: A Review
CNS & Neurological Disorders - Drug Targets Recent Development of Copolymeric Nano-Drug Delivery System for Paclitaxel
Anti-Cancer Agents in Medicinal Chemistry Marine Natural Products as a Promising Source of Therapeutic Compounds to Target Cancer Stem Cells
Current Medicinal Chemistry The Therapeutic Potential of Angiotensin-(1-7) as a Novel Renin- Angiotensin System Mediator
Mini-Reviews in Medicinal Chemistry Fetal Mesenchymal Stem Cells in Cancer Therapy
Current Stem Cell Research & Therapy Use of Chronic Disease Registries to Optimize Cardiovascular Health
Current Vascular Pharmacology The Emerging Role of Arginase in Endothelial Dysfunction in Diabetes
Current Vascular Pharmacology A Virtual Screening Approach for the Identification of High Affinity Small Molecules Targeting BCR-ABL1 Inhibitors for the Treatment of Chronic Myeloid Leukemia
Current Topics in Medicinal Chemistry B7-H3-targeted Radioimmunotherapy of Human Cancer
Current Medicinal Chemistry Application of Pharmacogenomic Approaches in the Study of Drug Response in Complex Diseases
Current Pharmacogenomics Rewiring the Heart: Stem Cell Therapy to Restore Normal Cardiac Excitability and Conduction
Current Stem Cell Research & Therapy Pancreatic Cancer: Promises and Failures of Target Therapies
Reviews on Recent Clinical Trials Impact of Ivabradine on Health-Related Quality of Life of Patients with Ischaemic Chronic Heart Failure
Current Vascular Pharmacology Current Treatment of the Pulmonary Arterial Hypertension
Current Respiratory Medicine Reviews Biomarkers in Molecularly Targeted Therapy for Cancer
Recent Patents on Biomarkers Episcopic 3D Imaging Methods: Tools for Researching Gene Function
Current Genomics